Overview

A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants

Status:
Completed
Trial end date:
2018-12-14
Target enrollment:
Participant gender:
Summary
The purpose of this 3 part study are; Part 1: to investigate the pharmacokinetic (PK), safety and tolerability of JNJ-61393215 suspension (ascending dose levels) after single oral dose administration under fasted conditions, Part 2: to evaluate the relative bioavailability of a solid JNJ-61393215 capsule formulation compared to a suspension of JNJ-61393215 under fasted conditions, and the effect of food on the PK of the solid JNJ-61393215 capsule formulation, Part 3: to investigate the PK, safety, and tolerability of JNJ-61393215 suspension (ascending dose levels) after 7 days of once daily dosing in under fasted conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC